Impact of Initial Influenza Exposure on Immunity in Infants — RFA-AI-27-019
Supports longitudinal infant influenza immunity studies to guide next-generation vaccine design.
The National Institute of Allergy and Infectious Diseases (NIAID) issued RFA-AI-27-019 on February 10, 2026, to support longitudinal infant cohort studies examining how initial and repeated natural influenza infections and vaccinations shape immune responses to future influenza exposures in infants and young children. The scientific rationale is that the first influenza exposure — whether a natura…
Influenza immune imprinting in infants — longitudinal cohort studies measuring how initial and repeated influenza infections and vaccinations shape childhood immunity.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Guides for this application
All guides →NIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
DocumentsGrant Work Plan Template: Work Packages, Gantt, Milestones, and Risks
Use this grant work plan template to structure work packages, tasks, owners, deliverables, Gantt timing, dependencies, and risk registers.
More from NIAID
All grants from this funder →NIAID Investigator-Initiated P01
🇺🇸NIAID · United States
Supports investigator-led infectious disease and immunology multi-project teams under NIAID.
Coccidioidomycosis Collaborative Research Centers — RFA-AI-27-012
🇺🇸NIAID · United States
Supports translational vaccine teams targeting valley fever through collaborative centers.
Tuberculosis Research Advancement Centers (TRACs) — RFA-AI-27-016
🇺🇸NIAID · United States
Supports tuberculosis research centers through shared resources and interdisciplinary teams.
Similar grants
Browse the directory →
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose
NIH · United States
Funds discovering and developing a medication or device to prevent or treat substance use disorders and overdose, in two phases.
Defense Health Agency SBIR Phase II
🇺🇸DHA · United States
Supports United States defense health teams maturing validated medical technologies toward practical military use.
Bioengineering Partnerships with Industry (BPI)
🇺🇸NIBIB · United States
Funds academia-industry partnerships for biomedical engineering development with sustained milestones and shared commercialization planning.
ARPA-H SBIR/STTR
🇺🇸ARPA-H · United States
Funds United States small businesses bridging health and neuroscience technologies from feasibility into advanced development.
ARPA-H Initiatives & Sprints
🇺🇸ARPA-H · United States
Runs fast-turnaround health technology opportunities in United States for high-potential exploratory science and engineering.
Assay Validation of High Quality Markers for Clinical Studies in Cancer
🇺🇸NIH · United States
Funds two years of analytical validation then three of clinical validation for a cancer biomarker assay that already works on human samples.